On the HCPLive ankylosing spondylitis page, resources on the topics of medical news and expert insight into the inflammatory disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on ankylosing spondylitis, and more.
February 14th 2024
A Mendelian randomization analysis provided new insights into the relationship between inflammatory cytokines and ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis.
Combination of TNFis and NSAIDs May Slow Ankylosing Spondylitis
Speaking at ACR 2016, the current chair of the Spondyloarthritis Research and Treatment Network (SPARTAN) presented data that showed that a combination of inflammatory drugs may inhibit ankylosis, the painful fusion of bones.
Long-Term Secukinumab Treatment Safe and Effective for Patients with Psoriatic Arthritis
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.
Adalimumab: Efficacy and Adverse Effects for Patients with Active Noninfectious Uveitis
The authors say that for uveitis “there is a large unmet medical need" for identifying other therapies. Adalimumab is associated with decreased visual impairment and decreased risk of uveitic flare, but more adverse events, according the results from a recent multinational phase 3 trial.
Golimumab Effective Against Uveitis Associated with Ankylosing Spondylitis
Retrospective study results indicate that golimumab may be a new and effective choice for maintaining remission and preventing recurrence of severe, recurrent anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis.
Study Shows TNF Inhibitors Prevent Relapse of Uveitis in Most Patients with Ankylosing Spondylitis
Adalimumab, infliximab, and etanercept, reduced the number of uveitis relapses in a retrospective, long-term study of uveitis patients with HLA-B27-positive ankylosing spondylitis who had taken one of these biological agents for at least 1 year.
Biosimilar Drugs for Psoriatic Arthritis, Other Conditions, One Step Closer to Approval
The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).
5 Factors that Predict Medication Nonadherence in Patients Taking Biologics for Rheumatic Disease
Analysis of questionnaire data has identified 5 factors that help predict which patients with chronic inflammatory rheumatic diseases such as psoriatic arthritis will abandon biologic treatment.
Long-Term Pneumonia Vaccine Efficacy in Patients with Psoriatic Arthritis
Blood analysis in patients with inflammatory rheumatic diseases such as psoriatic arthritis indicates that biologic medications do not reduce the efficacy of anti-pneumococcal polysaccharide vaccine, and that patients with such conditions may not need to be vaccinated more frequently than others.
New Indications for Psoriasis Drug Cosentyx Receive FDA Nod
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
What Makes Treating Psoriatic Arthritis So Expensive?
New research on the cost of treating psoriatic arthritis indicates that, on average, the annual bill for medical care and prescription medication totals just under $20,000 per patient, but that total costs vary greatly among individual patients.